The NITI Aayog report states that 65% of India's pharma supply chain relies on Chinese imports for APIs and KSMs.
Increased environmental compliance costs are currently impacting manufacturing and R&D activities within the domestic industry.
The report calls for improved industry-academia technology transfer to boost patent commercialization and startup innovation.
India remains a major global player, supplying significant volumes of generic medicines to the US, UK, and Africa.